Integration of existing IEC 61131-3 systems in an IEC 61499 distributed solution

The IEC 61499 standard allows to model and design new generation control systems, providing innovative concepts of software engineering (such as abstraction, encapsulation, reuse) to the world of control engineering. The industrial reception of the standard, however, is still in an early stage, also because its introduction results in the adoption of a programming paradigm profoundly different than the widespread IEC 61131-3. This paper presents a method for the integration of the two standards, that allows to exploit the benefits of both. The proposed architecture is based on the parallel execution of both environments that interact with each other through some specific interfaces. A test implementation of the architecture is also presented to demonstrate the feasibility of the proposed solution

An architecture to integrate IEC 61131-3 systems in an IEC 61499 distributed solution

The IEC 61499 standard has been developed to allow the modeling and design of distributed control systems, providing advanced concepts of software engineering (such as abstraction and encapsulation) to the world of control engineering. The introduction of this standard in already existing control environments poses challenges, since programs written using the widespread IEC 61131-3 programming standard cannot be directly executed in a fully IEC 61499 environment without reengineering effort. In order to solve this problem, this paper presents an architecture to integrate modules of the two standards, allowing the exploitation of the benefits of both. The proposed architecture is based on the coexistence of control software of the two standards. Modules written in one standard interact with some particular interfaces that encapsulate functionalities and information to be exchanged with the other standard. In particular, the architecture permits to utilize available run-times without modification, it allows the reuse of software modules, and it utilizes existing features of the standards. A methodology to integrate IEC 61131-3 modules in an IEC 61499 distributed solution based on such architecture is also developed, and it is described via a case study to prove feasibility and benefits. Experimental results demonstrate that the proposed solution does not add substantial load or delays to the system when compared to an IEC 61131-3 based solution. By acting on task period, it can achieve performances similar to an IEC 61499 solution

An inspection system for pharmaceutical glass tubes

Abstract: Syringes, vials and carpules for pharmaceutical products are usually made of borosilicate glass. Such containers are made by glass converting companies starting from single glass tubes. These glass containers can suffer from inclusions, air bubbles, stones, scratches and others issues, that can cause subsequent problems like product contamination with glass particulate or cracks in the glass. In recent years, more than 100 million units of drugs packaged in vials or syringes have been withdrawn from the market. As a consequence pharmaceutical companies are demanding an increased delivery of high quality products to manufacturers of glass containers and therefore of glass tubes. An automatic, vision based, quality inspection system can be devoted to perform such task, but specific process features requires the introduction of ad-hoc solutions: in the production lines tubes significantly vibrate and rotate, and the cylindrical surface of the tube needs to be inspected at 360 degrees. This paper presents the design, the development and the experimental evaluation of a vision system to control the quality of glass tubes, highlighting the specific solutions developed to manage vibrations and rotations, obtaining a 360 degree inspection. The system has been designed and tested in a real facility, and proved effective in identifying defects and impurities in the order of tens of microns

Dermatologia in ambito lavorativo

The main skin diseases in an occupational context are irritant and allergic contact dermatitis. These conditions are a very common cause of ill-health related to occupation. Despite a decrease of notifications to INAIL for occupational skin diseases in recent years, their burden is still high, so dermatologist may often be called for a consultation, giving his opinion about indemnity of the worker. This paper gives an overview of legal aspects concerning occupational dermatitis

L’invalidità civile

This article provides an overview on civil invalidity in Italy, starting from the first law, in 1939, in which the invalid subject was considered and a definition of invalid person was given. During the following years this status has been ascribed to even better defined categories of patients, and now a big system of invalidity calculation, economic and not economic social security benefits has been built. A detailed description of each benefit, including requirements and bureaucratic procedures, follows and a survey on the institutions involved, closes this articl

Un insolito caso di reazione anafilattica da farmaco: cenni clinici e riflessioni medico-legali

We report a case of a cutaneous ulcer in a 49 years-old patient with diabetes and hypertension. Penicillin in pownder for local use was prescribed. A severe anaphylactic reaction was observed. This case leads to some considerations concerning the off-label prescribing, that is to say the prescription of a registered medicine for a use that is not included in the product information. Thus off-label prescribing in dermatology may sometimes be clinically appropriate, it may be associated with a number of clinical, safety and legal issues. Off-label prescribing is acceptable if there is no suitable alternative and an appropriate process for informed consent is needed. The practice of prescribing off-label drugs is common among dermatologists, many of whom had misperceptions about which are the approved indications of the drug and about the legal ramifications of off-label therapies. The authors suggest that understanding the principles of off-label prescribing in conjunction with the mechanisms of drug action in diseases may help clinicians in increasing the safety of their patients and in avoiding legal litigations

Dermatologia e invalidità

Psoriasis is a skin disease, characterized by the presence of sharply demarcated plaques, typically appears as raised areas of inflamed skin covered with silvery white scaly skin. Its overall prevalence is approximately 2-3%. Although the etiology of psoriasis is not known, genetic, enviromental and immunologic factors appear to influence the susceptibility of the disease. Psoriasis can involve an invalidating state in its more serious shapes, like artropatic, amicrobic pustular and erythrodermic psoriasis. The authors propose a medical-legal classification of the disease, finalized to define of its invalidating degree and a connected practical case to the problem list, often underestimated

Complicanze in endoscopia digestiva.Aspetti clinici e medico-legali

The optimal outcome of endoscopy is conditioned by numerous factors: the most important are represented by trained endoscopists with standard techniques, by a systematized approach to event management, by a good documented patient informed consent and communication before and after the procedure. Complications are quite rare, but when they occur they can cause adverse events and patient injury, increasing the probability of malpractice actions. This article will focus on potential lawsuits that are likely to be pursued when there is the lack of one of these procedures

Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the “CARACAS” study

Background: Molecular characteristics of squamous cell anal carcinoma (SCAC) are poorly explored. Immune checkpoint inhibitors showed limited activity in phase I/II trials, but predictive and prognostic biomarkers are lacking. Patients and methods: In the phase II randomised trial CARACAS (NCT03944252), avelumab alone (Arm A) or with cetuximab (Arm B) was tested in pre-treated advanced SCAC , with overall response rate being the primary end-point. On pre-treatment tumour tissue samples, we assessed Human papillomavirus status, programmed-death ligand 1 (PD-L1) expression, mismatch repair proteins expression, tumour mutational burden (TMB) and comprehensive genomic profiling by FoundationOne CDx. Tumour-infiltrating lymphocytes were characterised on haematoxylin-eosine-stained samples. Primary objective was to describe response to immunotherapy in the CARACAS trial population according to molecular and histological characteristics. Secondary objectives were to assess progression-free survival (PFS) and overall survival (OS) according to molecular biomarkers. Results: High PD-L1 (>40 with combined positive score) was significantly more frequent in patients with disease control (p = 0.0109). High TMB (>10 mutations per megabase) was related to better OS (hazard ratio (HR) = 0.09; 95%confidence interval (CI) 0.01-0.68; p = 0.019) and PFS (HR = 0.44; 95%CI = 0.15-1.27; p = 0.129). High expression of PD-L1 conferred longer OS (HR = 0.46; 95%CI = 0.19-1.08; p = 0.075) and PFS (HR = 0.42; 95%CI = 0.20-0.92; p = 0.03). Neither OS (HR = 1.30; 95%CI = 0.72-2.36; p = 0.39) or PFS (HR = 1.31; 95%CI = 0.74-2.31; p = 0.357) was affected by high (>1.2) Tumour-infiltrating lymphocytes count. High TMB and PD-L1identified patients were with significantly better OS (HR = 0.33; 95%CI = 0.13-0.81; p = 0.015) and PFS (HR = 0.48; 95%CI = 0.23-1.00; p = 0.015). Conclusions: To our knowledge, TranslaCARACAS is the first study to document prognostic role of TMB and PD-L1 in advanced SCAC patients treated with immune checkpoint inhibitors